Our mission
We want to help ageing consumers to live a longer and happier life.
By providing the best self- management solutions for chronic metabolic conditions.
Metabolic health is under pressure by lifestyle and food choices. With age, metabolic syndrome may develop.
Metabolic syndrome is a disorder of energy utilization and storage, mainly manifesting as diabetes type 2.
The ageing population - and more and more young people - are confronted with a high risk for diabetes type 2.
Unfortunately, existing drugs are not curative. Even after initiation of treatment, patients face diabetes progression and side-effects.
In Germany, 40,000 new patients every month are newly diagnosed with diabetes type 2. Worldwide, 500 million people are living with diabetes type 2.
About perora GmbH
perora GmbH has its core competence in the development and marketing of high-quality medical products. We are a highly innovative start-up located on the Heidelberg research campus "Im Neuenheimer Feld". Here, perora GmbH develops dosage forms for otherwise unpleasantly ingestible substances with health benefits. Based on our innovative patent-protected bioformulation technology, years of research have succeeded in formulating the most important class of health-active dietary fibers, namely highly viscous fibers, in such a way that the ingestion of health-promoting dosages is easy and pleasant.
Our Team
Founded on scientifc innovation and clinical validation with a strong background in life-science company-building. Extensive experiences in production, nutritional counseling, strategic communication, and digital and D2C marketing.
Our Commitment
perora GmbH carries out its research and development work independently and autonomously. Production takes place at our own premises in Heidelberg. A first clinical study was also conducted in Heidelberg. perora GmbH is guided by international state-of-the-art evidence-based research with a focus on metabolic diseases and their prevention. The aspects of customer satisfaction and the integration of health-effective products with telemedical diagnostics and digital health play increasingly important roles in our product positioning.
Dr. Dirk Vetter, Founder & CEO
Prior to the founding of perora GmbH in Heidelberg in 2013:
Founder and CEO of the Heidelberg biotech start-up from which the pharmaceutical company Ascendis Pharma A/S emerged (listed on NASDAQ).
Founder and managing director of Graffinity Pharmaceuticals GmbH, from which the pharmaceutical company Santhera AG emerged (listed in Switzerland)
Research stations in Jena, Palo Alto and Basel
Doctorate in Biochemistry at the University of Hamburg
Dr. Kristina Schmidt, Founder & COO
Prior to the founding of perora GmbH in Heidelberg in 2013:
COO at Lipid Therapeutics GmbH
CEO at Graffinity Pharmaceuticals GmbH
Founder and COO Graffinity Pharmaceutical Design GmbH
Postdoc at IMB Jena
Prof. Dr. Hasslacher
"In summary, long-term administration of SATIOLIPID resulted in significantly improved diabetes control and body weight loss in people with type 2 diabetes."
At the time of the clinical trial, the name "satiolipid" was used for REDIA drinkable granules. Satiolipid is REDIA.
Product & Application
REDIA offers a particularly easy way to supplement meals with high-dose fiber that effectively curbs blood sugar spikes. In order for REDIA to develop it's full effect, it should be taken either once or twice daily before each main meal. For this purpose, REDIA should be taken 20-30 minutes prior to the meal. The
contents of a sachet should be put in an empty glass, which is then filled with still cold or lukewarm water (approx. 200 ml). The suspension should be taken immediately, unchewed after stirring well. Afterwards, intake of at least one more glass of water is recommended. REDIA can then mix well in the stomach with the food pulp resulting from the following meal and develop its attenuating effect on the blood sugar peaks.
About REDIA
REDIA is the first and only supplement with a granted EFSA-health claim for lowering post-meal blood sugar.
REDIA is a novel fiber supplement that is indicated for type 2 diabetics and prediabetics that seek to reduce their blood glucose levels naturally and to prevent pill stacking and subsequential disease escalation.
REDIA is easy and convenient to use, clinically validated and available online and in stationary pharmacies in order to match customer purchase preferences.
Mode of action
The unique dietary fiber included in REDIA is a highly pure, completely soluble cellulose of plant origin. In the stomach, REDIA thickens the food pulp, which is directly noticeable as a feeling of satiety. By thickening the food pulp, gastric emptying and nutrient release are slowed down. The dietary fiber used in REDIA is of a particularly high-viscosity quality. Therefore, REDIA is the only dietary supplement with the Health Claim for attenuating the rise in blood sugar after a meal. In addition to this modified cellulose, the granules also contain lipids, which allow for high-dose
and convenient ingestion as a granulated drink.
How REDIA works
REDIA is taken 20-30 Minutes prior to a meal in form of a suspention.
After ingestion of REDIA, the granules release their highly viscous fibers in the stomach.
The food pulp is thickened and the secretion of appetite-reducing hormones is stimulated. This results in a more rapid feeling of satiety.
In the small intestine, nutrients are absorbed more slowly, so that the blood glucose level reaches a significantly lower value.
The physical binding of bile salts to the highly viscous fibers in the food pulp also lowers cholesterol levels. In the colon, the fibers have a positive effect on intestinal bacteria.
In addtition, the fibers bind excess water and thus facilitate and regulate bowel movements. REDIA thus allows for effective blood sugar, cholesterol, weight and IBS Management.
